A Comparative Pharmacokinetic Study of Fexuprazan 10 mg: Demonstrating Bioequivalence with the Reference Formulation and Evaluating Steady State

• Autores principales: Wonsuk Shin (Autor), A-Young Yang (Autor), Hyung Park (Autor), Hyejung Lee (Autor), Hyounggyoon Yoo (Autor), Anhye Kim (Autor)
• Formato: Libro
• Publicado: MDPI AG, 2023-08-01T00:00:00Z.
• Materias: article
• Acceso en línea: Connect to this object online.

Fexuprazan is a potassium-competitive acid blocker approved for treating gastric-acid-related diseases. Although the effectiveness of the recent formulation fexuprazan 10 mg has been demonstrated in Phase 3 clinical trials, data on the pharmacokinetics (PKs) of administering fexuprazan 10 mg twice d...